Plain-English translation of NCT06859203 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing fluciclovine (18F) PET/CT, a specialized imaging scan designed to detect prostate cancer that has returned after treatment. The study focuses on men whose previous standard scans came back negative or unclear, leaving them and their doctors uncertain about whether cancer is still present. Researchers want to see if this medication and scan approach can provide clearer answers.
Some men with prostate cancer recurrence have previous scans that don't show where the cancer is, making it hard for doctors to plan the next steps in treatment. This trial exists to find out whether this new scan can detect cancer that other tests might miss, giving patients and doctors better information for making treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will have one fluciclovine PET/CT scan as part of your routine clinical care at one of two specialized centers in Germany. Three independent doctors will review your scan images to help interpret results. You will complete follow-up assessments at 1 month (answering a brief questionnaire about any changes to your treatment plan) and at 12 months (providing additional imaging, blood work, and treatment outcome information). The entire study lasts 12 months from your initial scan.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Germany
Sponsor
Technical University of Munich
Enrollment target
~94 participants
Started
March 2025
Primary completion
December 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matthias Eiber, MD
Technical University of Munich
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.